Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT added to metastasis-directed radiotherapy for oligorecurrent prostate cancer
NL-OMON52631Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Metastasis progression-free survival. Started Mar 2020; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52631.